On #WorldThyroidDay, we proudly reaffirm our commitment to improving the lives of patients with thyroid-related conditions. At MBX, we’re advancing our novel investigational parathyroid hormone replacement therapy designed to address the significant unmet needs in care for those with #hypoparathyroidism – a rare endocrine disorder often associated with thyroid surgery. Rooted in science, we are focused on delivering better health outcomes for patients everywhere. Together, let’s raise awareness, support those affected, and continue pushing innovation forward. American Thyroid Association, Inc. (ATA)
MBX Biosciences, Inc.
Biotechnology Research
Carmel, IN 8,429 followers
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.
About us
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.
- Website
-
http://www.mbxbio.com
External link for MBX Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Carmel, IN
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
Carmel, IN 46032, US
Employees at MBX Biosciences, Inc.
Updates
-
MBX Biosciences is proud to celebrate 50 years of toxicology expertise with Michael A. Dorato, PhD, DABT, Fellow ATS, FRSB, our Senior Vice President, Discovery & Non-Clinical Development! Mike’s leadership continues to set the standard in the field, including earning his recertification with the American Board of Toxicology, Inc. through 2030. As one of its inaugural members in 1980, his decades of experience and dedication to continuous learning inspire us all. His contributions embody MBX’s core values of scientific innovation, collaboration, teamwork, and integrity. Thank you, Mike, for your outstanding contributions to the broader field of toxicology and to MBX as we work to advance #metabolic and #endocrine treatments for patients in need! #MBXSpotlight #MBXellence
-
-
Next month, our CEO & Co-Founder, Kent Hawryluk, will present at and participate in 1x1 meetings at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. Learn more and access the live webcasts in the full release: https://lnkd.in/eJEsT4CC
-
Today, we shared our Q1 2025 financial results. View our recent corporate highlights and upcoming milestones in the press release: https://lnkd.in/exJs-t9b
-
We proudly congratulate our MBX Biosciences scientific co-founder and Indiana University Bloomington Professor Richard DiMarchi, Ph.D., on receiving the 2024 Tu Youyou Award. This prestigious recognition honors his pioneering contributions to the development of GLP-1 receptor agonists, a class of therapeutics that has transformed the treatment of #metabolic disorders. His research was foundational to our pipeline, and we wish him continued success in improving the lives of patients.
-
-
2025 promises to be our most important year to date as we continue to pursue our mission of helping people with endocrine and metabolic disorders live fuller and healthier lives. Our progress continues to be fueled by novel science and the talented people driving these innovations. We are pleased to have welcomed 10 new MBXers this year and look forward to welcoming more individuals to help us execute our mission. If you are looking to join a dynamic company that values transparency, integrity, teamwork, and innovation, check out our current job openings: mbxbio.com/careers/
-
#ICYMI, our CEO & Co-Founder, Kent Hawryluk, will present at the Citizens Life Sciences Conference and the RBC 2025 Global Healthcare Conference this month. Learn more and access the live webcasts in the full release: https://lnkd.in/eGPNFYrQ Citizens JMP RBC Capital Markets
Next month, our CEO & Co-Founder, Kent Hawryluk, will present at the Citizens Life Sciences Conference and the RBC 2025 Global Healthcare Conference. Learn more and access the live webcast in the full release: https://lnkd.in/eGPNFYrQ Citizens JMP RBC Capital Markets
-
Next month, our CEO & Co-Founder, Kent Hawryluk, will present at the Citizens Life Sciences Conference and the RBC 2025 Global Healthcare Conference. Learn more and access the live webcast in the full release: https://lnkd.in/eGPNFYrQ Citizens JMP RBC Capital Markets
-
On #WorldHealthDay, we reaffirm our commitment to advancing care for patients with rare metabolic and endocrine disorders. By driving innovation and access to treatment, we strive to create a future where every patient receives the care they need and deserve. We can make meaningful progress toward #HealthForAll for those who need it most. World Health Organization #HopefulFutures
-
Today, we announced the appointment of Steve Hoerter as an independent director to MBX’s Board of Directors. Mr. Hoerter brings over three decades of #pharma commercialization and executive leadership experience as well as a proven track record of building and growing #lifescience companies. Read our full press release: https://lnkd.in/eGkyKbJA